Six quarters after it was co-founded, seeded and incubated by Atlas Venture, Kymera Therapeutics LLC debuted with a $30M series A round led by Atlas, with participation from Lilly Ventures and Amgen Ventures. In the words of Atlas partner Bruce Booth, co-founder and chairman, the Cambridge, Mass.-based firm is seeking to "drug the undruggable" by harnessing the power of targeted protein degradation to deliver therapeutic benefits.